Top DC Head Hunters and Where to Find Them

Job hunting is an incredibly difficult task in today’s economy. Even with a competitive skill set, a great portfolio and impeccable references, a search can be grim. In order to stand out, one could use Nels Olson a successful executive head hunter, their connections and experience in the candidate’s prospective industry equals a guarantee they…

Details

Helping Spur Economic Growth through Business Tax Credits

Those who are looking for a great example of how a state can successfully use tax credits to encourage significant economic growth should look at Maine’s New Markets Capital Investment Program. The program functions by attracting investment money to lower income communities. A tax credit is given to individuals and businesses who make equity investments…

Details

Legg Mason announces merger of EnTrust Capital and Permal Group

Leading investment firm Legg Mason has announced a combination of Permal, its alternative fund solutions provider with EnTrust Capital, a giant independent hedge fund investor, in what financial experts say will create a powerful asset management firm with a huge financial muscle.

Details

Washington D.C. Executive Recruiters

Finding the perfect candidate for a job can be a daunting and time-consuming task. Additionally, the pressure of choosing the right person can be unduly burdensome. Washington D.C. is home to many executive recruiters like Nels Olson that can assist next time your company seeks a new employee. Lucas Group The Lucas Group maintains recruitment…

Details

Government Real Estate in the District

It is a known fact that Franklin Haney Company has begun to notice redeveloping in the area as more wealth is poured into the city through tourism and residencies. Washington D.C., especially among the government buildings, has been growing a reputation for implementing environmentally friendly building features that are hot on the market. The new…

Details

GlaxoSmithKline beats sales forecasts thanks to HIV drugs boost

Higher revenues from HIV drugs and flu vaccines have boosted quarterly sales and earnings at GlaxoSmithKline, more than offsetting a continued fall in sales for respiratory treatments. Sales rose by 9% to £6.13bn in the three months to the end of September, the third quarter of the company’s financial year. Analysts’ average forecasts were for…

Details